A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
Document type:
Meeting Abstract
Author(s):
Grimm, MO; Machiels, JP; Wülfing, C; Richel, D; Treiber, U; de Groot, M; Beuzeboc, P; Farrell, J; Colman, J; El-Hariry, I